Altimeter Growth Corp 2 - Class A

AGCB | $10.105 0.05% 0.0%

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-90.15% volume)
Earnings Calendar:
Market Cap: $ 465,840,500
https://www.altimetergrowth.com/AGCB.html
Sec Filling | Patents | n/a employees

Altimeter Growth Corporation 2 is a special purpose investment vehicle sponsored by Altimeter Capital Management (“Altimeter”) and formed to invest in and help bring a world-class technology company to the public markets.

vehicles

add to watch list Paper trade email alert is off

BM Technologies Inc - Class A

BMTX 4 | $1.545 0.98% 0.0% 2.8K

Information

(0.0% 1d) (-7.8% 1m) (-47.4% 1y) (0.0% 2d) (0.7% 3d) (-5.5% 7d) (-84.04% volume)
Earnings Calendar:
Market Cap: $ 18,638,529
https://bmtech.pro
Sec Filling | Patents | 2 employees

BM Technologies, Inc. is among the largest mobile-first banking platforms in the U.S., providing access to checking and savings accounts, personal loans and credit cards. BankMobile was named the “Most Innovative Bank” by LendIt Fintech in 2019, providing an alternative banking technology to the traditional model. It is focused on technology, innovation, easy-to-use products and education with the mission of being “customer-obsessed” and creating “customers for life.” The BankMobile platform employs a multi-partner distribution model, known as “Banking-as-a-Service” (BaaS), that enables the acquisition of customers at higher volumes and substantially lower expense than traditional banks. Its efficient operating model enables partner banks to provide low-cost banking services to low/middle-income Americans who have been left behind by the high-fee model of “traditional” banks. Today, the BankMobile BaaS platform is provided to colleges and universities and currently serves over two million account-holders, and provides disbursement services at 722 campuses (covering one out of every three students in the U.S.). BM Technologies, Inc. is a technology company and is not a bank and provides banking services through its partner banks.

education acquisitions msa

add to watch list Paper trade email alert is off

Eledon Pharmaceuticals Inc

ELDN | $1.97 -8.8% -10.2% 100K

Manufacturing

(0.0% 1d) (-7.1% 1m) (-12.1% 1y) (0.0% 2d) (-8.8% 3d) (5.9% 7d) (-46.95% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 48,881,866
http://novustherapeutics.com/
Sec Filling | Patents | 10 employees

(US) Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company’s lead compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is widely recognized for its prominent role in immune regulation. CD40L is primarily expressed on activated CD4+ T cells, platelets and endothelial cells while the CD40 receptor is constitutively expressed on antigen presenting cells such as B cells, macrophages, and dendritic cells. By blocking CD40L and not the CD40 receptor, AT-1501 inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches. Blocking CD40L also increases polarization of CD4+ lymphocytes to Tregs, a specialized subpopulation of T cells that act to suppress an immune response, thus creating a more tolerogenic environment, which is especially important for autoimmune diseases and in the transplant setting. Furthermore AT-1501 is an IgG1 antibody specifically engineered to cripple the Fc effector function to potentially improve safety, as well as potentially provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other approaches.

als ceiling treatment antibody t-cell

add to watch list Paper trade email alert is off

Healthcare Services Acquisition Corp - Class A

HCAR | $10.11 0.15% 0.0%

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-99.85% volume)
Earnings Calendar:
Market Cap: $ 334,843,200
https://www.healthcarespac.com
Sec Filling | Patents | 113000 employees

ealthcare Services Acquisition Corporation is a special purpose acquisition company led by a team of investors, operators, and leaders in the healthcare space, seeking to partner with ambitious management who are constrained by capital availability, operational expertise, and national-scale capabilities. The company closed its upsized and oversubscribed IPO on December 28, 2020, with $331.2 million in trust.

acquisitions

add to watch list Paper trade email alert is off

INDUS Realty Trust Inc

INDT 4 | $66.99 0.02% 0.0% 0

Real Estate and Rental and Leas...

(0.0% 1d) (0.0% 1m) (0.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (407.85% volume)
Earnings Calendar: 2023-03-06
Market Cap:
http://www.griffinindustrial.com/
Sec Filling | Patents | 33 employees

Griffin Industrial Realty, Inc. is a real estate business principally engaged in developing, acquiring, managing and leasing industrial/warehouse properties. Griffin recently completed the sale of an approximately 40,000 square foot office/flex building and currently owns 41 buildings totaling approximately 4.6 million square feet (4.2 million of which is industrial/warehouse space) in Connecticut, Pennsylvania, North Carolina and Florida in addition to over 3,400 acres of undeveloped land.

add to watch list Paper trade email alert is off

Orla Mining Ltd

ORLA | $4.01 0.0% 230K

Mining, Quarrying, and Oil and ...

(0.0% 1d) (13.3% 1m) (-11.3% 1y) (0.0% 2d) (0.0% 3d) (1.0% 7d) (-11.74% volume)
Earnings Calendar:
Market Cap: $ 1,263,446,720
https://www.orlamining.com
Sec Filling | Patents | n/a employees

(CA) Orla Mining Ltd. of Canada operates as a mineral exploration company. The Company focuses on acquiring mineral exploration opportunities.

msa mining

add to watch list Paper trade email alert is off

PhenixFIN Corp

PFX 4 | $44.1 -1.78% 2.03% 260

Finance and Insurance

(0.0% 1d) (2.3% 1m) (25.2% 1y) (0.0% 2d) (0.0% 3d) (3.1% 7d) (56360.0% volume)
Earnings Calendar: 2024-02-14
Market Cap: $ 90,867,609
http://www.medleycapitalcorp.com/
Sec Filling | Patents | n/a employees

(US) PhenixFIN Corporation is an internally managed, closed-end, business development company (“BDC”). Its experienced team is focused on current income generation coupled with capital appreciation with a focus on net asset value (“NAV”) accretion to drive total shareholder returns. henixFIN has a broad network of relationships and deep expertise in originating, structuring, executing and managing credit and equity investments. Its portfolio generally consists of senior secured first lien loans, senior secured second lien loans, and equity.

security

add to watch list Paper trade email alert is off

Roth CH Acquisition II Co

ROCC 4 | $37.47 0.61% 5.7M

(0.0% 1d) (0.0% 1m) (-6.4% 1y) (-2.0% 2d) (-2.0% 3d) (0.0% 7d) (2506.29% volume)
Earnings Calendar: 2023-08-01
Market Cap:
https://www.pennvirginia.com
Sec Filling | Patents | 87 employees

(US) Penn Virginia Corporation is a pure-play independent oil and gas company engaged in the development and production of oil, NGLs, and natural gas, with operations in the Eagle Ford shale in south Texas.

add to watch list Paper trade email alert is off

Star Equity Holdings Inc

STRR | $0.865 -2.32% 1.14% 23K

Manufacturing

(0.0% 1d) (-3.5% 1m) (19.4% 1y) (0.0% 2d) (-3.4% 3d) (0.0% 7d) (4.79% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 13,708,695
https://www.digirad.com/
Sec Filling | Patents | 636 employees

(US) Star Equity Holdings, Inc. is a diversified holding company committed to growing shareholder value through operational excellence and disciplined capital allocation.

add to watch list Paper trade email alert is off